Millennium CEO foresight averts Velcade shortage; Cardinal tops Gartner's supply chain list;

> Give high marks to Millennium CEO Deborah Dunsire, who anticipates no shortage of U.S.- and EU-recalled cancer drug Velcade because she ratcheted up volumes with two CMOs as quality concerns grew with supplier Ben Venue Labs. Article

> Cardinal Health has earned top honors in Gartner's 2011 Healthcare Supply Chain list; competition among life sciences manufacturers has "tightened." Report

> GE Healthcare and construction-management company M+W Group have teamed to build biopharma manufacturing capabilities--for vaccines, insulin and biosimilars--in countries aiming to reduce dependence on imports. Article

> European regulators have recommended a third precautionary recall of drugs made by beleaguered Ben Venue Labs--this time, it's for a batch of the antiviral Vistide. Announcement

> QRxPharma has signed DSM Pharmaceutical Products as manufacturer of MoxDuo pain-management capsules. Item

> Advanced BioScience Laboratories has named Intercell vet Claire Zhang to direct GMP development and optimization programs as head of the contractor's downstream bioprocessing group. Item

> Gaymar Industries, purchase by Stryker last year, will eliminate 160 jobs with the closing of two New York plants. Article

> Chinese drugmakers will risk the loss of operating permits if they use prohibited chemicals in drugs or are involved in fake drug production. Story

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.